Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to $705000.0.

  • Praxis Precision Medicines' Amortizatization of Intangibles fell 6483.79% to $705000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 1232.41%. This contributed to the annual value of $5.0 million for FY2024, which is 49856.63% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Amortizatization of Intangibles stood at $705000.0, which was down 6483.79% from $987000.0 recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Amortizatization of Intangibles registered a high of $2.0 million during Q3 2024, and its lowest value of -$375000.0 during Q1 2022.
  • For the 4-year period, Praxis Precision Medicines' Amortizatization of Intangibles averaged around $517666.7, with its median value being $218000.0 (2023).
  • As far as peak fluctuations go, Praxis Precision Medicines' Amortizatization of Intangibles skyrocketed by 84575.47% in 2024, and later tumbled by 6483.79% in 2025.
  • Praxis Precision Medicines' Amortizatization of Intangibles (Quarter) stood at -$196000.0 in 2022, then surged by 211.22% to $218000.0 in 2023, then surged by 537.61% to $1.4 million in 2024, then tumbled by 49.28% to $705000.0 in 2025.
  • Its Amortizatization of Intangibles was $705000.0 in Q3 2025, compared to $987000.0 in Q2 2025 and $1.2 million in Q1 2025.